Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junine Toy

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2022
Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, CanadaKyle A Thompson, Gabriel Blank, Junine Toy, et al.
AIDS (London, England)|April 5, 2017
Emergent drug resistance with integrase strand transfer inhibitor-based regimensKatherine J Lepik, P Richard Harrigan, Benita Yip, et al.
BMC Public Health|October 31, 2023
Examining the secondary impacts of the COVID-19 pandemic on syndemic production and PrEP use among gay, bisexual and other men who have sex with men (GBM) in Vancouver, CanadaJordan M Sang, David M Moore, Lu Wang, et al.
Antiviral Therapy|May 12, 2015
Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, CanadaKatherine J Lepik, Benita Yip, Rachel A McGovern, et al.
Plos One|August 31, 2023
Identification of people with low prevalence diseases in administrative healthcare records: A case study of HIV in British Columbia, CanadaScott D Emerson, Taylor McLinden, Paul Sereda, et al.
AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines|March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases|June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose ResponsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Liver International : Official Journal of the International Association for the Study of the Liver|March 11, 2022
Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, CanadaKyle A Thompson, Gabriel Blank, Junine Toy, et al.
AIDS (London, England)|April 5, 2017
Emergent drug resistance with integrase strand transfer inhibitor-based regimensKatherine J Lepik, P Richard Harrigan, Benita Yip, et al.
BMC Public Health|October 31, 2023
Examining the secondary impacts of the COVID-19 pandemic on syndemic production and PrEP use among gay, bisexual and other men who have sex with men (GBM) in Vancouver, CanadaJordan M Sang, David M Moore, Lu Wang, et al.
Antiviral Therapy|May 12, 2015
Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, CanadaKatherine J Lepik, Benita Yip, Rachel A McGovern, et al.
Plos One|August 31, 2023
Identification of people with low prevalence diseases in administrative healthcare records: A case study of HIV in British Columbia, CanadaScott D Emerson, Taylor McLinden, Paul Sereda, et al.
AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines|March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases|June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose ResponsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Pageof 3